RecruitingNCT02998788
Risk Evaluation and Management in Heart Failure
Sponsor
Ruijin Hospital
Enrollment
1,000 participants
Start Date
Jun 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
This is an prospective study conducted in a Chinese heart failure population. The study investigates the effects of cardiovascular disease risk factors such as lifestyle behaviors,biomarkers and intermediate diseases on heart failure prognosis.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is evaluating the risks of heart failure getting worse and developing tools to better manage patients who are hospitalized with heart failure — including those with fluid buildup in the lungs, shock from a failing heart, or very high-output heart problems.
**You may be eligible if...**
- You are 18 years or older
- You are admitted to the hospital with heart failure symptoms such as fluid in the lungs, swelling, or cardiogenic shock (heart not pumping enough blood)
- You have had impaired heart function confirmed by an echocardiogram (ultrasound of the heart)
- You are able to give informed consent
**You may NOT be eligible if...**
- You refuse to participate in the baseline assessment or follow-up visits
- You have serious other illnesses that significantly reduce life expectancy
- Your condition is too severe or unstable to safely participate
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02998788
Related Trials
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288653 locations
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370638 locations
Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker
NCT075631531 location
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257135 locations
The Salt Study for Heart Failure
NCT075605921 location